Background Visceral leishmaniasis (VL) is a severe disease caused by infection with protozoa of the genus Leishmania. Classic VL is characterized by a systemic infection of phagocytic cells and an intense activation of the inflammatory response. It is unclear why 90% of infected individuals do not develop the disease while a minority develop the classical form. Furthermore, among those that develop disease, a small group progresses to more severe form that is unresponsive to treatment. The presence of inflammatory mediators in serum could theoretically help to control the infection. However, there is also a release of anti-inflammatory mediators that could interfere with the control of parasite multiplication. In this study, we took advantage of the spectrum of outcomes to test the hypothesis that the immune profile of individuals infected with Leishmania (L.) infantum is associated with the development and severity of disease. Methodology/Principal Findings Sera from patients with confirmed diagnosis of VL were evaluated for the presence of numerous molecules, and levels compared with healthy control and asymptomatic infected individuals. Conclusions/Principal Findings Although differences were not observed in LPS levels, higher levels of sCD14 were detected in VL patients. Our data suggest that L. infantum may activate the inflammatory response via CD14, stimulating a generalized inflammatory response with production of several cytokines and soluble molecules, including IFN-γ, IL-27, IL-10, IL-6 and sCD14. These molecules were strongly associated with hepatosplenomegaly, neutropenia and thrombocytopenia. We also observed that IL-6 levels greater than 200 pg/ml were strongly associated with death. Together our data reinforce the close relationship of IFN-γ, IL-10, IL-6, TNF-α and IL-27 in the immune dynamics of VL and suggest the direct participation of sCD14 in the activation of the immune response against L. infantum.
References
[1]
Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis Worldwide and Global Estimates of Its Incidence.Plos one. 2012; 7: e35671. doi: 10.1371/journal.pone.0035671. pmid:22693548
[2]
Organization WH. Control of the leishmaniasis: report of a meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva, 22–26 March 2010.WHO technical report series. 2010; 949.
[3]
Badaro R, Jones TC, Carvalho EM, Sampaio D, Reed SG, Barral A, et al. New perspectives on a subclinical form of visceral leishmaniasis.J Infect Dis. 1986; 154: 1003–1011. pmid:3782864 doi: 10.1093/infdis/154.6.1003
[4]
Sampaio MJ, Cavalcanti NV, Alves JG, Filho MJ, Correia JB. Risk factors for death in children with visceral leishmaniasis.PLoS Negl Trop Dis. 2010; 4: e877. doi: 10.1371/journal.pntd.0000877. pmid:21072238
[5]
Bacellar O, M.Carvalho E. Imunopatogênese da Leishmaniose Visceral.Gazeta Médica da Bahia. 2005; 75.
[6]
Costa AS, Costa GC, Aquino DM, Mendonca VR, Barral A, Barral-Netto M, et al. Cytokines and visceral leishmaniasis: a comparison of plasma cytokine profiles between the clinical forms of visceral leishmaniasis.Mem Inst Oswaldo Cruz. 2012; 107: 735–739. pmid:22990961 doi: 10.1590/s0074-02762012000600005
[7]
Costa DL, Rocha RL, Carvalho RM, Lima-Neto AS, Harhay MO, Costa CH, et al. Serum cytokines associated with severity and complications of kala-azar.Pathog Glob Health. 2013; 107: 78–87. doi: 10.1179/2047773213Y.0000000078. pmid:23683334
[8]
Duthie MS, Guderian J, Vallur A, Bhatia A, Lima dos Santos P, Vieira de Melo E, et al. Alteration of the serum biomarker profiles of visceral leishmaniasis during treatment.Eur J Clin Microbiol Infect Dis. 2014; 33: 639–649. doi: 10.1007/s10096-013-1999-1. pmid:24173820
[9]
Gama ME, Gomes CM, Silveira FT, Laurenti MD, Goncalves Eda G, Silva AR, et al. Severe visceral leishmaniasis in children: the relationship between cytokine patterns and clinical features.Rev Soc Bras Med Trop. 2013; 46: 741–745. doi: 10.1590/0037-8682-0203-2013. pmid:24474016
[10]
Gautam S, Kumar R, Maurya R, Nylen S, Ansari N, Rai M, et al. IL-10 neutralization promotes parasite clearance in splenic aspirate cells from patients with visceral leishmaniasis.J Infect Dis. 2011; 204: 1134–1137. doi: 10.1093/infdis/jir461. pmid:21881130
[11]
Hailu A, van der Poll T, Berhe N, Kager PA. Elevated plasma levels of interferon (IFN)-gamma, IFN-gamma inducing cytokines, and IFN-gamma inducible CXC chemokines in visceral leishmaniasis.Am J Trop Med Hyg. 2004; 71: 561–567. pmid:15569785
[12]
Khoshdel A, Alborzi A, Rosouli M, Taheri E, Kiany S, Javadian MH. Increased levels of IL-10, IL-12, and IFN- in patients with visceral leishmaniasis.Braz J Infect Dis. 2009; 13: 44–46. pmid:19578629 doi: 10.1590/s1413-86702009000100010
[13]
Peruhype-Magalhaes V, Martins-Filho OA, Prata A, Silva Lde A, Rabello A, Teixeira-Carvalho A, et al. Immune response in human visceral leishmaniasis: analysis of the correlation between innate immunity cytokine profile and disease outcome.Scand J Immunol. 2005; 62: 487–495. pmid:16305646 doi: 10.1111/j.1365-3083.2005.01686.x
[14]
Peruhype-Magalhaes V, Martins-Filho OA, Prata A, Silva Lde A, Rabello A, Teixeira-Carvalho A, et al. Mixed inflammatory/regulatory cytokine profile marked by simultaneous raise of interferon-gamma and interleukin-10 and low frequency of tumour necrosis factor-alpha(+) monocytes are hallmarks of active human visceral Leishmaniasis due to Leishmania chagasi infection.Clin Exp Immunol. 2006; 146: 124–132. pmid:16968407 doi: 10.1111/j.1365-2249.2006.03171.x
[15]
Nylen S, Sacks D. Interleukin-10 and the pathogenesis of human visceral leishmaniasis.Trends Immunol. 2007; 28: 378–384. pmid:17689290 doi: 10.1016/j.it.2007.07.004
[16]
Ansari NA, Kumar R, Gautam S, Nylen S, Singh OP, Sundar S, et al. IL-27 and IL-21 are associated with T cell IL-10 responses in human visceral leishmaniasis.J Immunol. 2011; 186: 3977–3985. doi: 10.4049/jimmunol.1003588. pmid:21357266
[17]
Hunter CA, Kastelein R. Interleukin-27: balancing protective and pathological immunity.Immunity. 2012; 37: 960–969. doi: 10.1016/j.immuni.2012.11.003. pmid:23244718
[18]
Andrade TM, Carvalho EM, Rocha H. Bacterial infections in patients with visceral leishmaniasis.J Infect Dis. 1990; 162: 1354–1359. pmid:2230265 doi: 10.1093/infdis/162.6.1354
[19]
Ramachandran G. Gram-positive and gram-negative bacterial toxins in sepsis: a brief review.Virulence. 2014; 5: 213–218. doi: 10.4161/viru.27024. pmid:24193365
[20]
Santos-Oliveira JR, Regis EG, Leal CR, Cunha RV, Bozza PT, Da-Cruz AM. Evidence that lipopolisaccharide may contribute to the cytokine storm and cellular activation in patients with visceral leishmaniasis.PLoS Negl Trop Dis. 2011; 5: e1198. doi: 10.1371/journal.pntd.0001198. pmid:21765960
[21]
Saúde. BMd. Manual de vigilancia e controle da leishmaniose visceral.Brasília: Editora do Ministério da Saúde. 2006.
[22]
Skraba CM, de Mello TF, Pedroso RB, Ferreira EC, Demarchi IG, Aristides SM, et al. Evaluation of the reference value for the Montenegro skin test.Rev Soc Bras Med Trop. 2015; 48: 437–444. doi: 10.1590/0037-8682-0067-2015. pmid:26312935
[23]
Belo VS, Struchiner CJ, Barbosa DS, Nascimento BW, Horta MA, da Silva ES, et al. Risk Factors for Adverse Prognosis and Death in American Visceral Leishmaniasis: A Meta-analysis.PLoS Negl Trop Dis. 2014; 8: e2982. doi: 10.1371/journal.pntd.0002982. pmid:25058582
[24]
Diro E, Lynen L, Ritmeijer K, Boelaert M, Hailu A, van Griensven J. Visceral Leishmaniasis and HIV coinfection in East Africa.PLoS Negl Trop Dis. 2014; 8: e2869. doi: 10.1371/journal.pntd.0002869. pmid:24968313
[25]
Belo VS, Werneck GL, Barbosa DS, Simoes TC, Nascimento BW, da Silva ES, et al. Factors associated with visceral leishmaniasis in the americas: a systematic review and meta-analysis.PLoS Negl Trop Dis. 2013; 7: e2182. doi: 10.1371/journal.pntd.0002182. pmid:23638203
[26]
Leite AI, Araújo LB. Leishmaniose visceral: aspectos epidemiológicos relacionados aos óbitos em Mossoró-RN.Rev Patol Tropi. 2013; 42: 301–308. doi: 10.5216/rpt.v42i3.26928
[27]
de Araujo VE, Morais MH, Reis IA, Rabello A, Carneiro M. Early clinical manifestations associated with death from visceral leishmaniasis.PLoS Negl Trop Dis. 2012; 6: e1511. doi: 10.1371/journal.pntd.0001511. pmid:22347514
[28]
Costa CH, Pereira HF, Araujo MV. [Visceral leishmaniasis epidemic in the State of Piaui, Brazil, 1980–1986].Rev Saude Publica. 1990; 24: 361–372. pmid:2101528 doi: 10.1590/s0034-89101990000500003
[29]
Liu L, Wang L, Zhao Y, Wang Y, Wang Z, Qiao Z. Testosterone attenuates p38 MAPK pathway during Leishmania donovani infection of macrophages.Parasitol Res. 2006; 99: 189–193. pmid:16547729 doi: 10.1007/s00436-006-0168-1
[30]
Travi BL, Osorio Y, Melby PC, Chandrasekar B, Arteaga L, Saravia NG. Gender is a major determinant of the clinical evolution and immune response in hamsters infected with Leishmania spp.Infect Immun. 2002; 70: 2288–2296. pmid:11953362 doi: 10.1128/iai.70.5.2288-2296.2002
[31]
Maegraith B. Pathological processes in malaria.Trans R Soc Trop Med Hyg. 1948; 41: 687–704. pmid:18865438
[32]
Barral-Netto M, Badaro R, Barral A, Almeida RP, Santos SB, Badaro F, et al. Tumor necrosis factor (cachectin) in human visceral leishmaniasis.J Infect Dis. 1991; 163: 853–857. pmid:1901333 doi: 10.1093/infdis/163.4.853
[33]
Clark IA, Alleva LM, Mills AC, Cowden WB. Pathogenesis of malaria and clinically similar conditions.Clin Microbiol Rev. 2004; 17: 509–539, table of contents. pmid:15258091 doi: 10.1128/cmr.17.3.509-539.2004
[34]
Costa CH, Werneck GL, Costa DL, Holanda TA, Aguiar GB, Carvalho AS, et al. Is severe visceral leishmaniasis a systemic inflammatory response syndrome? A case control study.Rev Soc Bras Med Trop. 2010; 43: 386–392. pmid:20802936 doi: 10.1590/s0037-86822010000400010
[35]
Goto H, Prianti M. Immunoactivation and immunopathogeny during active visceral leishmaniasis.Rev Inst Med Trop Sao Paulo. 2009; 51: 241–246. pmid:19893975 doi: 10.1590/s0036-46652009000500002
[36]
Caldas A, Favali C, Aquino D, Vinhas V, van Weyenbergh J, Brodskyn C, et al. Balance of IL-10 and interferon-gamma plasma levels in human visceral leishmaniasis: implications in the pathogenesis.BMC Infect Dis. 2005; 5: 113. pmid:16364177 doi: 10.1186/1471-2334-5-113
[37]
Carvalho EM, Bacellar O, Brownell C, Regis T, Coffman RL, Reed SG. Restoration of IFN-gamma production and lymphocyte proliferation in visceral leishmaniasis.J Immunol. 1994; 152: 5949–5956. pmid:8207220
[38]
Bacellar O, Brodskyn C, Guerreiro J, Barral-Netto M, Costa CH, Coffman RL, et al. Interleukin-12 restores interferon-gamma production and cytotoxic responses in visceral leishmaniasis.J Infect Dis. 1996; 173: 1515–1518. pmid:8648233 doi: 10.1093/infdis/173.6.1515
[39]
Janeway CA Jr. The immunobiology of the T cell response to Mls locus disparate stimulator cells.Curr Top Microbiol Immunol. 1988; 137: 171–176. pmid:2970945 doi: 10.1007/978-3-642-50059-6_25
[40]
de Oliveira FA, Vanessa Oliveira Silva C, Damascena NP, Passos RO, Duthie MS, Guderian JA, et al. High levels of soluble CD40 ligand and matrix metalloproteinase-9 in serum are associated with favorable clinical evolution in human visceral leishmaniasis.BMC Infect Dis. 2013; 13: 331. doi: 10.1186/1471-2334-13-331. pmid:23870715
[41]
Belkhelfa M, Rafa H, Medjeber O, Arroul-Lammali A, Behairi N, Abada-Bendib M, et al. IFN-gamma and TNF-alpha Are Involved During Alzheimer Disease Progression and Correlate with Nitric Oxide Production: A Study in Algerian Patients.J Interferon Cytokine Res. 2014. doi: 10.1089/jir.2013.0085
[42]
Wang SM, Liao YT, Hu YS, Ho TS, Shen CF, Wang JR, et al. Immunophenotype expressions and cytokine profiles of influenza A H1N1 virus infection in pediatric patients in 2009.Dis Markers. 2014; 2014: 195453. doi: 10.1155/2014/195453. pmid:24696530
[43]
Sabat R, Grutz G, Warszawska K, Kirsch S, Witte E, Wolk K, et al. Biology of interleukin-10.Cytokine Growth Factor Rev. 2010; 21: 331–344. doi: 10.1016/j.cytogfr.2010.09.002. pmid:21115385
[44]
Verma S, Kumar R, Katara GK, Singh LC, Negi NS, Ramesh V, et al. Quantification of parasite load in clinical samples of leishmaniasis patients: IL-10 level correlates with parasite load in visceral leishmaniasis.PLoS One. 2010; 5: e10107. doi: 10.1371/journal.pone.0010107. pmid:20404924
[45]
Silva JM, Zacarias DA, de Figueiredo LC, Soares MR, Ishikawa EA, Costa DL, et al. Bone marrow parasite burden among patients with New World kala-azar is associated with disease severity.Am J Trop Med Hyg. 2014; 90: 621–626. doi: 10.4269/ajtmh.13-0376. pmid:24615127
[46]
Wynick C, Petes C, Gee K. Interleukin-27 Mediates Inflammation During Chronic Disease.J Interferon Cytokine Res. 2014. doi: 10.1089/jir.2013.0154
[47]
Aderka D, Le JM, Vilcek J. IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice.J Immunol. 1989; 143: 3517–3523. pmid:2584704
[48]
Diehl S, Anguita J, Hoffmeyer A, Zapton T, Ihle JN, Fikrig E, et al. Inhibition of Th1 differentiation by IL-6 is mediated by SOCS1.Immunity. 2000; 13: 805–815. pmid:11163196 doi: 10.1016/s1074-7613(00)00078-9
[49]
Diehl S, Rincon M. The two faces of IL-6 on Th1/Th2 differentiation.Mol Immunol. 2002; 39: 531–536. pmid:12431386 doi: 10.1016/s0161-5890(02)00210-9
[50]
Bacellar O, Lessa H, Schriefer A, Machado P, Ribeiro de Jesus A, Dutra WO, et al. Up-regulation of Th1-type responses in mucosal leishmaniasis patients.Infect Immun. 2002; 70: 6734–6740. pmid:12438348 doi: 10.1128/iai.70.12.6734-6740.2002
[51]
Xu C, Chang A, Hack BK, Eadon MT, Alper SL, Cunningham PN. TNF-mediated damage to glomerular endothelium is an important determinant of acute kidney injury in sepsis.Kidney Int. 2014; 85: 72–81. doi: 10.1038/ki.2013.286. pmid:23903370
[52]
Kinra P, Dutta V. Serum TNF alpha levels: a prognostic marker for assessment of severity of malaria.Trop Biomed. 2013; 30: 645–653. pmid:24522135
[53]
Landmann R, Knopf HP, Link S, Sansano S, Schumann R, Zimmerli W. Human monocyte CD14 is upregulated by lipopolysaccharide.Infect Immun. 1996; 64: 1762–1769. pmid:8613389
[54]
Tuon FF, Fernandes ER, Duarte MI, Amato VS. Expression of TLR2 and TLR4 in lesions of patients with tegumentary American leishmaniasis.Rev Inst Med Trop Sao Paulo. 2012; 54: 159–163. pmid:22634888 doi: 10.1590/s0036-46652012000300008
[55]
Landmann R, Reber AM, Sansano S, Zimmerli W. Function of soluble CD14 in serum from patients with septic shock.J Infect Dis. 1996; 173: 661–668. pmid:8627030 doi: 10.1093/infdis/173.3.661
[56]
Karima R, Matsumoto S, Higashi H, Matsushima K. The molecular pathogenesis of endotoxic shock and organ failure.Mol Med Today. 1999; 5: 123–132. pmid:10203736 doi: 10.1016/s1357-4310(98)01430-0
[57]
Gluck T, Silver J, Epstein M, Cao P, Farber B, Goyert SM. Parameters influencing membrane CD14 expression and soluble CD14 levels in sepsis.Eur J Med Res. 2001; 6: 351–358. pmid:11549517
